Treatment of candidemia in adult patients without neutropenia - an inconvenient truth

Critical Care

Volumn 15, Issue 1, 2011, Pages

  Póvoa, Pedro ^a   Gonçalves Pereira, João ^a  

^a HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; CREATININE; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN B; FUNGAL PROTEIN;

ADULT; CANDIDEMIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; KIDNEY FAILURE; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; KIDNEY DISEASE; REVIEW; STANDARD; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDEMIA; ECHINOCANDINS; FLUCONAZOLE; FUNGAL PROTEINS; HUMANS; KIDNEY DISEASES; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84855461750     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9414     Document Type: Note

References (15)

1. Pappas PG, Kauff man CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. 10.1086/596757, 19191635.
2. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161-189. 10.1086/380796, 14699449.
3. Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008, 83:1011-1021. 10.4065/83.9.1011, 18775201.
4. Mills EJ, Perri D, Cooper C, Nachega JB, Wu P, Tleyjeh I, Phillips P. Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis. Ann Clin Microbiol Antimicrob 2009, 8:23. 10.1186/1476-0711-8-23, 2713200, 19558681.
5. Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006, 355:1154-1159. 10.1056/NEJMct060052, 16971721.
6. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482. 10.1056/NEJMoa066906, 17568028.
7. Gotzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA 2006, 295:1172-1174. 10.1001/jama.295.10.1172, 16522840.
8. Kaul S, Diamond GA. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials. Prog Cardiovasc Dis 2007, 49:284-299. 10.1016/j.pcad.2006.10.001, 17185116.
9. Sobel JD, Revankar SG. Echinocandins - first-choice or first-line therapy for invasive candidiasis?. N Engl J Med 2007, 356:2525-2526. 10.1056/NEJMe078078, 17568034.
10. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002, 49(Suppl 1):37-41.
11. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001, 32:686-693. 10.1086/319211, 11229835.
12. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999, 29:1402-1407. 10.1086/313498, 10585786.
13. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2000, CD000969.
14. Di Bonaventura G, Spedicato I, Picciani C, D'Antonio D, Piccolomini R. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother 2004, 48:4453-4456. 10.1128/AAC.48.11.4453-4456.2004, 525414, 15504881.
15. Canton E, Peman J, Gobernado M, Viudes A, Espinel-Ingroff A. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother 2004, 48:2477-2482. 10.1128/AAC.48.7.2477-2482.2004, 434204, 15215097.